Abstract: Systemic Lupus Erythematosus (SLE) is a rather frequent disease in Iran. In the past 13 years, 449 patients with SLE attended the SLE clinic. Lupus nephritis was discovered in 278 of them. The purpose of this study is to demonstrate the caracteristics of lupus nephritis in Iran (percentage of proteinuria, hematuria, leucocyturia, casts, renal insufficiency, hypertension, and patterns of renal biopsy), to compare them to the remaining patients with SLE ...
Abstract: The evaluation of the inflammatory state of Behcet`s Disease and it's quantification is most difficult. The difficulty is due to the recurrent attacks and spontaneous remissions that characterizes the disease. In IBDDAM the patients is evaluated on several weeks or months. Each attack is measured separately and given an index. The obtained indexes are added together and the total is divided by the number of months of the evaluation period. ...
Abstract: Cytotoxic drugs as the only remittent agents in posterior uveitis (PU) and/or retinal vasculitis (RV) of Aehcet's disease(BD) is generally accepted today. However which cytotoxic is the least harmful and yet efficient is questionable. The safety of long term use of MTX in rheumatoid arthritis made us to use this drug in ocular Behcet. Our prelimi-nary report to the first APLAR Symposium for Treatment of Rheumatic Diseases in Korea, stowed ...
Abstract: Pulse cyclophosphamide (PCP) is a well established method for the treatment of lupus nephritis. PCP seems to produce better results with lesser side effects, than oral cytotoxic drugs. We presenthere, our experience with this method, in 84 patients. All patients had a WHO type IV histological lesion, on light microscopy, Proteinuria, hematuria, leucocyturia, casts, BUN, creatinine, and blood pressure were measured before starting PCP and after each one. The first ...
Abstract: The prognosis of Lupus Nephritis has dramatically changed since the introduction of cytotoxic drugs in their treatment. Different protocols have been proposed to reach this goal. Pulse cyclophosphamide (PCP) was first introduced in the treatment of Systemic Lupus Erythematosus by Sessoms & Kovarsky in 1984. Austin and Colleagues demonstrated it's superiority upon other regimens in Lupus Nephritis in 1986. Pulse Cyclophosphamide is now a well established method for the treatment ...
Abstract: Since our first report in 1987 to the XIth EULAR Congress of Rheumatology several reports had proved the efficacy of pulsed cyclophosphamide (PCP) in severe posterior uveitis (PU) and retinal vasculitis (RV) of Behcet's Disease (BD). The aim of this report is to show the outcome of 45 patients who have been followed for more than 2 years. PCP was administered as lg/m2/body surface, once per month, with 0.5 mg ...
Abstract: Posterior uveitis and retinal vasculitis are the most serious lesions of ocular Behcet. Pulse cyclophosphamide and cyclosporine A are the most efficient treatment. Oral cytotoxic drugs (cyclophosphamide, chlorambucil , and azathioprine) are less efficient. We present here our first impression on weekly pulsed methotrexate (MTX). MTX was administereted as 7.5 mg weekly in 3 divided doses, every 12 hours Prednisolone was given as 0.5 mg/kg/day. 23 patients with posterior uveitis (PU) ...
Abstract: PCP was administered as 1 g cyclophosphsmide/m2/body surface, once per month, with 0.5mg prednisolone/kg/day, to 71 patients with severe posterior uveitis (PU) and/or retinal vasculitis (RV) , A Disease Activity Index (DAI) was calculated for each section of each eye, before the first PCP and then after each one. When a remission was obtained the gap between, PCP was increased gradually and prednisolone was tapered. If the result remained ...
Abstract: Pulse cyclophosphamide (PCP) is a well established method for the treatment of lupus nephritis. PCP seems to produce better results, and lesser side effects, than oral cytotoxic drugs. We present here, our experience with this method, in 51 patients. All patients had a WHO type IV histological lesion, on light microscopy. Proteinuria, hematuria, leucocyturia, casts, BUN, creatinine, and blood pressure were measured before starting PCP and after each one. The first ...
Abstract: SLE is not a rare disease in Iran. In the past 14 years, we have seen 503 cases. Renal manifestations were discovered in 317 of them (63%). The female ratio was 87%. All of them had proteinuria, but only 50% had a proteinuria superior to 500 mg per 24 hours. 60% had hematuria, 45% leucocyturia, and 42% had urinary casts. Serum creatinine was elevated in 16% of patients. Arterial hyper-tension ...